This segment focuses on the development, manufacturing, and distribution of point-of-care (POC) diagnostic instruments and reagents. EKF Diagnostics offers a range of hand-held and desktop analyzers for various applications, including hemoglobin measurement (DiaSpect Tm, Hemo Control), A1c testing (Quo-Lab A1c, Quo-Test A1c), and lactate analysis (Lactate Scout 4). Research and development efforts are directed towards improving the accuracy, speed, and ease of use of POC devices, as well as expanding the range of analytes that can be measured. Technologies employed include spectrophotometry, electrochemical sensors, and microfluidics. The patient impact is significant, as POC testing enables rapid diagnosis and monitoring of conditions like anemia, diabetes, and lactate levels, leading to faster treatment decisions and improved patient outcomes. EKF Diagnostics holds a strong market position in POC hemoglobin and A1c testing, with a focus on providing cost-effective and reliable solutions. Future opportunities include expanding into new POC testing areas and developing connected health solutions. Regulatory compliance is crucial, with products requiring approvals from regulatory bodies like the FDA and CE marking. Partnerships with distributors and healthcare providers are essential for market access and sales.

This segment encompasses the development, manufacturing, and distribution of diagnostic instruments and reagents used in central laboratories. EKF Diagnostics provides a range of analyzers for various tests, including chemistry (Altair 240, Excel), hematology (Hemo Control, HemataStat II), and serology. Research and development activities focus on improving the performance, throughput, and automation of laboratory tests, as well as expanding the menu of available assays. Technologies used include spectrophotometry, centrifugation, and immunoassay techniques. The segment addresses a wide range of therapeutic areas, including hematology, clinical chemistry, and serology, impacting patient care through accurate and timely diagnostic results. EKF Diagnostics aims to provide high-quality, reliable solutions for central laboratories, competing with larger diagnostic companies. Future opportunities include developing new assays, expanding into molecular diagnostics, and integrating with laboratory information systems. Regulatory compliance is essential, with products requiring approvals from regulatory bodies. Partnerships with laboratory service providers and distributors are key for market access and sales.

This segment focuses on the development and commercialization of molecular diagnostic solutions, including rapid tests and related products. EKF Diagnostics offers products for early detection of colorectal cancer (Hema-Screen Serology) and Strep A infection treatment (QuStick Strep A). Research and development efforts are focused on expanding the range of rapid tests and improving their accuracy and ease of use. Technologies employed include lateral flow assays and immunoassay techniques. The segment addresses infectious diseases and cancer, impacting patient care through rapid and accurate diagnosis. EKF Diagnostics aims to provide cost-effective and reliable solutions for point-of-care and laboratory settings. Future opportunities include expanding into new disease areas and developing molecular diagnostic tests for companion diagnostics. Regulatory compliance is crucial, with products requiring approvals from regulatory bodies. Partnerships with healthcare providers and distributors are essential for market access and sales.